دورية أكاديمية
أعرض في EDS

Proton pump inhibitors may increase the risk of cisplatin-induced acute kidney injury in patients with nasopharyngeal carcinoma: a prospective cohort study.

التفاصيل البيبلوغرافية
العنوان: Proton pump inhibitors may increase the risk of cisplatin-induced acute kidney injury in patients with nasopharyngeal carcinoma: a prospective cohort study.
المؤلفون: Luo H; Specialty of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524002, China., Yi G; Specialty of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524002, China., Tang H; Specialty of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524002, China., Chen L; Specialty of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524002, China., Hu L; School of Public Health of Guangdong Medical University, Zhanjiang, 524023, China., Yang D; Specialty of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524002, China., Chen Z; Specialty of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524002, China., Li H; Specialty of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524002, China., Zhan D; Specialty of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524002, China., Yu Y; Specialty of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524002, China., Zeng Y; Specialty of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524002, China., Cai Y; Specialty of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524002, China., Wu J; Clinical Research Service Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524002, China. wujiay@gdmu.edu.cn., Liu H; Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-communicable Diseases, Key Laboratory of Prevention and Management of Chronic Kidney Disease of Zhanjiang City, Institute of Nephrology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524002, China. liuhf@gdmu.edu.cn.
المصدر: Scientific reports [Sci Rep] 2024 Aug 13; Vol. 14 (1), pp. 18839. Date of Electronic Publication: 2024 Aug 13.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Cisplatin*/adverse effects , Proton Pump Inhibitors*/adverse effects , Proton Pump Inhibitors*/administration & dosage , Acute Kidney Injury*/chemically induced , Acute Kidney Injury*/epidemiology , Nasopharyngeal Carcinoma*/drug therapy , Nasopharyngeal Carcinoma*/complications , Nasopharyngeal Neoplasms*/drug therapy, Humans ; Male ; Female ; Middle Aged ; Prospective Studies ; Adult ; Risk Factors ; Antineoplastic Agents/adverse effects ; Aged ; Incidence
مستخلص: Cisplatin is the most commonly used platinum-based treatment for nasopharyngeal carcinoma (NPC). However, its clinical application is limited owing to its nephrotoxicity and gastrointestinal reactions. Proton pump inhibitors (PPIs) have been reported to increase nephrotoxicity risk in previous studies. We aimed to evaluate whether PPIs increase cisplatin-induced nephrotoxicity in patients with NPC. In total, 295 patients were included in this prospective cohort study: 145 in the PPIs group and 150 in the non-PPIs group. All patients underwent cisplatin-based induction chemotherapy, followed by cisplatin-based concurrent chemoradiotherapy. The PPIs group received 40 mg of intravenous esomeprazole sodium for 7 days in each chemotherapy cycle. Chi-squared test and logistic regression analyses with odds ratios and 95% confidence intervals were applied to assess the association between PPIs and the risk of acute kidney injury (AKI). AKI incidence in the PPIs group was significantly higher than that in the non-PPIs group (P = 0.005). After adjusting for various confounders including demographic features, clinical features, and renal function indices, PPIs use was significantly associated with a higher AKI risk (odds ratio: 2.775; 95% confidence interval 1.280-6.020; P = 0.010). The incidences of acute and chronic kidney diseases were similar between both groups (P > 0.05), whereas the incidence of nausea was lower in the PPIs group than in the non-PPIs group (P = 0.029). This study has shown that PPIs use may increase the risk of cisplatin-induced acute nephrotoxicity in patients with NPC.
(© 2024. The Author(s).)
References: Anticancer Drugs. 1994 Apr;5(2):177-93. (PMID: 8049501)
Cancer. 1996 Oct 1;78(7):1477-82. (PMID: 8839554)
Crit Rev Oncol Hematol. 2017 Mar;111:144-151. (PMID: 28259289)
J Exp Clin Cancer Res. 2015 Aug 22;34:85. (PMID: 26297142)
Am J Kidney Dis. 2014 Oct;64(4):558-66. (PMID: 24927897)
Cancer Chemother Pharmacol. 2017 May;79(5):943-949. (PMID: 28364288)
Ther Clin Risk Manag. 2018 Jul 25;14:1279-1285. (PMID: 30100726)
J Clin Oncol. 2021 Mar 1;39(7):840-859. (PMID: 33405943)
Mol Cell. 2017 Mar 16;65(6):965-973. (PMID: 28306512)
Front Pharmacol. 2017 Dec 12;8:911. (PMID: 29311921)
J Clin Oncol. 2000 Feb;18(3):463-7. (PMID: 10653861)
Lancet. 2019 Jul 6;394(10192):64-80. (PMID: 31178151)
J Cell Mol Med. 2021 Mar;25(5):2703-2713. (PMID: 33605079)
Semin Nephrol. 2003 Sep;23(5):460-4. (PMID: 13680535)
Kidney Int. 2014 Oct;86(4):837-44. (PMID: 24646856)
Br J Clin Pharmacol. 2007 Dec;64(6):819-23. (PMID: 17635502)
Kidney Int. 2015 Jan;87(1):62-73. (PMID: 25317932)
Oncol Nurs Forum. 2012 Mar;39(2):157-65. (PMID: 22374489)
J Nephrol. 2018 Feb;31(1):15-25. (PMID: 28382507)
N Engl J Med. 2014 Jul 3;371(1):58-66. (PMID: 24988558)
Oncologist. 2018 Jul;23(7):762-e79. (PMID: 29445029)
Pharmazie. 2022 Jun 1;77(6):196-201. (PMID: 35751163)
Gastroenterology. 2017 Sep;153(3):702-710. (PMID: 28583827)
Eur Respir J. 2011 Apr;37(4):888-94. (PMID: 20650984)
Lancet. 2016 Oct 15;388(10054):1883-1892. (PMID: 27567279)
Biomed Res Int. 2014;2014:937429. (PMID: 25250341)
Oncologist. 2017 May;22(5):609-619. (PMID: 28438887)
Int J Cancer. 2010 Jul 1;127(1):207-19. (PMID: 19876915)
J Am Soc Nephrol. 2016 Oct;27(10):3153-3163. (PMID: 27080976)
Br J Clin Pharmacol. 2021 Jul;87(7):2967-2976. (PMID: 33368448)
Redox Biol. 2020 May;32:101464. (PMID: 32092686)
Curr Treat Options Oncol. 2020 Oct 3;21(12):92. (PMID: 33009956)
J Palliat Med. 2010 Jul;13(7):815-8. (PMID: 20636150)
Int J Clin Pharmacol Ther. 2023 Jun;61(6):246-254. (PMID: 36971321)
Age (Dordr). 2015 Dec;37(6):112. (PMID: 26534724)
Tohoku J Exp Med. 2009 Nov;219(3):177-86. (PMID: 19851045)
Lancet Oncol. 2012 Feb;13(2):163-71. (PMID: 22154591)
Kidney Int. 2008 May;73(9):994-1007. (PMID: 18272962)
Med Oncol. 2021 Aug 6;38(9):108. (PMID: 34357466)
Am J Kidney Dis. 2020 Apr;75(4):497-507. (PMID: 31606235)
Kidney Int. 2017 Jun;91(6):1482-1494. (PMID: 28237709)
Cancer Invest. 2011 Aug;29(7):494-500. (PMID: 21740087)
Pharmacotherapy. 2019 Apr;39(4):443-453. (PMID: 30779194)
Nephrology (Carlton). 2006 Oct;11(5):381-5. (PMID: 17014549)
J Enzyme Inhib Med Chem. 2016 Aug;31(4):538-45. (PMID: 26018420)
Clin Sci (Lond). 2019 Jul 25;133(14):1609-1627. (PMID: 31315969)
Nat Rev Nephrol. 2013 Feb;9(2):77-85. (PMID: 23247572)
فهرسة مساهمة: Keywords: Acute kidney injury; Chemotherapy; Chronic kidney disease; Nasopharyngeal carcinoma; Proton pump inhibitors
المشرفين على المادة: Q20Q21Q62J (Cisplatin)
0 (Proton Pump Inhibitors)
0 (Antineoplastic Agents)
تواريخ الأحداث: Date Created: 20240813 Date Completed: 20240813 Latest Revision: 20240816
رمز التحديث: 20240816
مُعرف محوري في PubMed: PMC11322290
DOI: 10.1038/s41598-024-69821-6
PMID: 39138312
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-2322
DOI:10.1038/s41598-024-69821-6